Leases

9 Months Ended

Jun. 27, 2020

Leases [Abstract]

Leases

Leases

Lessee Activity - Leases where Hologic is the Lessee

        The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

        The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of June 27, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as a finance lease on the balance sheet as of June 27, 2020.

        Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of June 27, 2020 was 2.6%.

        The following table presents supplemental balance sheet information related to the Company's operating and finance leases:

		June 27, 2020
	Balance Sheet Location	Operating Leases		Finance Lease
Assets
Lease right-of-use assets	Other assets	$	83.0	$	—
Liabilities
Operating lease liabilities (current)	Accrued expenses	$	22.9	$	—
Finance lease liabilities (current)	Finance lease obligations - short term	$	—	$	1.8
Operating lease liabilities (non-current)	Other long-term liabilities	$	68.3	$	—
Finance lease liabilities (non-current)	Finance lease obligations - long term	$	—	$	17.9

        The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

        The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

	As of June 27, 2020
	Operating Leases		Finance Lease
Weighted average remaining lease term	5.71		7.89
Weighted average discount rate	2.0	%	5.1	%

        The following table provides information related to the Company’s operating and finance leases:

		Three Months Ended June 27, 2020		Nine Months Ended June 27, 2020
Operating lease cost (a)		$	6.9	$	20.8
Finance lease cost - amortization of right-of-use assets		$	—	$	0.3
Finance lease cost - interest cost		$	0.3	$	0.8
Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows from finance leases	$	0.3	$	0.8
	Operating cash flows from operating leases	$	6.1	$	17.8
	Financing cash flows from finance leases	$	0.4	$	1.3
	Total cash paid for amounts included in the measurement of lease liabilities	$	6.8	$	19.9
ROU assets arising from entering into new operating lease obligations		$	6.0	$	10.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and nine months ended June 27, 2020.

        The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of June 27, 2020:

Fiscal Year	Operating Leases		Finance Lease
2020 remaining	$	6.0	$	0.7
2021	24.2		2.9
2022	19.6		3.0
2023	13.0		3.0
2024	10.4		3.0
Thereafter	23.9		11.4
Total future minimum lease payments	97.1		24.0
Less: imputed interest	(5.9)		(4.3)
Present value of lease liabilities	$	91.2	$	19.7

Lessor Activity - Leases where Hologic is the Lessor

        Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 4% of the Company’s consolidated revenue for both the three and nine months ended June 27, 2020.

        In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $19.7 million as of June 27, 2020.

Leases

Leases

Lessee Activity - Leases where Hologic is the Lessee

        The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

        The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of June 27, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as a finance lease on the balance sheet as of June 27, 2020.

        Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of June 27, 2020 was 2.6%.

        The following table presents supplemental balance sheet information related to the Company's operating and finance leases:

		June 27, 2020
	Balance Sheet Location	Operating Leases		Finance Lease
Assets
Lease right-of-use assets	Other assets	$	83.0	$	—
Liabilities
Operating lease liabilities (current)	Accrued expenses	$	22.9	$	—
Finance lease liabilities (current)	Finance lease obligations - short term	$	—	$	1.8
Operating lease liabilities (non-current)	Other long-term liabilities	$	68.3	$	—
Finance lease liabilities (non-current)	Finance lease obligations - long term	$	—	$	17.9

        The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

        The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

	As of June 27, 2020
	Operating Leases		Finance Lease
Weighted average remaining lease term	5.71		7.89
Weighted average discount rate	2.0	%	5.1	%

        The following table provides information related to the Company’s operating and finance leases:

		Three Months Ended June 27, 2020		Nine Months Ended June 27, 2020
Operating lease cost (a)		$	6.9	$	20.8
Finance lease cost - amortization of right-of-use assets		$	—	$	0.3
Finance lease cost - interest cost		$	0.3	$	0.8
Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows from finance leases	$	0.3	$	0.8
	Operating cash flows from operating leases	$	6.1	$	17.8
	Financing cash flows from finance leases	$	0.4	$	1.3
	Total cash paid for amounts included in the measurement of lease liabilities	$	6.8	$	19.9
ROU assets arising from entering into new operating lease obligations		$	6.0	$	10.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and nine months ended June 27, 2020.

        The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of June 27, 2020:

Fiscal Year	Operating Leases		Finance Lease
2020 remaining	$	6.0	$	0.7
2021	24.2		2.9
2022	19.6		3.0
2023	13.0		3.0
2024	10.4		3.0
Thereafter	23.9		11.4
Total future minimum lease payments	97.1		24.0
Less: imputed interest	(5.9)		(4.3)
Present value of lease liabilities	$	91.2	$	19.7

Lessor Activity - Leases where Hologic is the Lessor

        Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 4% of the Company’s consolidated revenue for both the three and nine months ended June 27, 2020.

        In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $19.7 million as of June 27, 2020.

Leases

Leases

Lessee Activity - Leases where Hologic is the Lessee

        The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

        The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of June 27, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as a finance lease on the balance sheet as of June 27, 2020.

        Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of June 27, 2020 was 2.6%.

        The following table presents supplemental balance sheet information related to the Company's operating and finance leases:

		June 27, 2020
	Balance Sheet Location	Operating Leases		Finance Lease
Assets
Lease right-of-use assets	Other assets	$	83.0	$	—
Liabilities
Operating lease liabilities (current)	Accrued expenses	$	22.9	$	—
Finance lease liabilities (current)	Finance lease obligations - short term	$	—	$	1.8
Operating lease liabilities (non-current)	Other long-term liabilities	$	68.3	$	—
Finance lease liabilities (non-current)	Finance lease obligations - long term	$	—	$	17.9

        The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

        The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

	As of June 27, 2020
	Operating Leases		Finance Lease
Weighted average remaining lease term	5.71		7.89
Weighted average discount rate	2.0	%	5.1	%

        The following table provides information related to the Company’s operating and finance leases:

		Three Months Ended June 27, 2020		Nine Months Ended June 27, 2020
Operating lease cost (a)		$	6.9	$	20.8
Finance lease cost - amortization of right-of-use assets		$	—	$	0.3
Finance lease cost - interest cost		$	0.3	$	0.8
Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows from finance leases	$	0.3	$	0.8
	Operating cash flows from operating leases	$	6.1	$	17.8
	Financing cash flows from finance leases	$	0.4	$	1.3
	Total cash paid for amounts included in the measurement of lease liabilities	$	6.8	$	19.9
ROU assets arising from entering into new operating lease obligations		$	6.0	$	10.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and nine months ended June 27, 2020.

        The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of June 27, 2020:

Fiscal Year	Operating Leases		Finance Lease
2020 remaining	$	6.0	$	0.7
2021	24.2		2.9
2022	19.6		3.0
2023	13.0		3.0
2024	10.4		3.0
Thereafter	23.9		11.4
Total future minimum lease payments	97.1		24.0
Less: imputed interest	(5.9)		(4.3)
Present value of lease liabilities	$	91.2	$	19.7

Lessor Activity - Leases where Hologic is the Lessor

        Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 4% of the Company’s consolidated revenue for both the three and nine months ended June 27, 2020.

        In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $19.7 million as of June 27, 2020.

Leases

Leases

Lessee Activity - Leases where Hologic is the Lessee

        The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

        The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of June 27, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as a finance lease on the balance sheet as of June 27, 2020.

        Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of June 27, 2020 was 2.6%.

        The following table presents supplemental balance sheet information related to the Company's operating and finance leases:

		June 27, 2020
	Balance Sheet Location	Operating Leases		Finance Lease
Assets
Lease right-of-use assets	Other assets	$	83.0	$	—
Liabilities
Operating lease liabilities (current)	Accrued expenses	$	22.9	$	—
Finance lease liabilities (current)	Finance lease obligations - short term	$	—	$	1.8
Operating lease liabilities (non-current)	Other long-term liabilities	$	68.3	$	—
Finance lease liabilities (non-current)	Finance lease obligations - long term	$	—	$	17.9

        The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

        The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

	As of June 27, 2020
	Operating Leases		Finance Lease
Weighted average remaining lease term	5.71		7.89
Weighted average discount rate	2.0	%	5.1	%

        The following table provides information related to the Company’s operating and finance leases:

		Three Months Ended June 27, 2020		Nine Months Ended June 27, 2020
Operating lease cost (a)		$	6.9	$	20.8
Finance lease cost - amortization of right-of-use assets		$	—	$	0.3
Finance lease cost - interest cost		$	0.3	$	0.8
Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows from finance leases	$	0.3	$	0.8
	Operating cash flows from operating leases	$	6.1	$	17.8
	Financing cash flows from finance leases	$	0.4	$	1.3
	Total cash paid for amounts included in the measurement of lease liabilities	$	6.8	$	19.9
ROU assets arising from entering into new operating lease obligations		$	6.0	$	10.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and nine months ended June 27, 2020.

        The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of June 27, 2020:

Fiscal Year	Operating Leases		Finance Lease
2020 remaining	$	6.0	$	0.7
2021	24.2		2.9
2022	19.6		3.0
2023	13.0		3.0
2024	10.4		3.0
Thereafter	23.9		11.4
Total future minimum lease payments	97.1		24.0
Less: imputed interest	(5.9)		(4.3)
Present value of lease liabilities	$	91.2	$	19.7

Lessor Activity - Leases where Hologic is the Lessor

        Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 4% of the Company’s consolidated revenue for both the three and nine months ended June 27, 2020.

        In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $19.7 million as of June 27, 2020.